Drug-product development for highly potent APIs (HPAPIs) is challenging. This executive summary in Japanese of our webinar provides best practices for developing and manufacturing highly potent compounds, infrastructure requirements that can facilitate development, and accelerated timelines to clinic and market. Case studies review the development, rapid scaling, and commercial production of HPAPI drug substance, as well as integrated containment requirements for particle engineering and drug product. To learn more, please read this executive summary.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center